Tiga Tablet 60 mg contains Ticagrelor 60 mg, a potent antiplatelet medication designed to prevent recurrent cardiovascular events in patients with a history of myocardial infarction (heart attack) or those at high risk of thrombotic events. Ticagrelor belongs to the P2Y12 receptor antagonist class and works by preventing platelets from clumping together, thereby reducing the formation of dangerous blood clots in the arteries.

Tiga 60 mg is commonly prescribed for long-term secondary prevention of cardiovascular events, especially in adults who have stabilized after a myocardial infarction. It is often used in combination with low-dose aspirin as part of dual antiplatelet therapy to provide optimal protection against recurrent heart attacks and strokes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Ticagrelor 60 mg

Mechanism of Action

Ticagrelor exerts its effects by selectively and reversibly blocking the P2Y12 receptor on platelets:

• Antiplatelet activity – Inhibits ADP-mediated platelet activation and aggregation, reducing the risk of clot formation in arteries.

• Reversible action – Unlike some other antiplatelet agents, Ticagrelor’s effect is reversible, allowing better control of platelet function in case of bleeding or prior to surgical procedures.

• Rapid onset – Provides fast and consistent platelet inhibition, which is critical in preventing thrombotic events in high-risk patients.

By maintaining proper platelet inhibition, Ticagrelor lowers the risk of recurrent cardiovascular events while balancing safety concerns related to bleeding.

Indications

Tiga Tablet 60 mg is indicated for:

• Long-term prevention of atherothrombotic events in patients with a history of myocardial infarction

• Reduction of risk of cardiovascular death, recurrent heart attack, or stroke

• Secondary prevention in high-risk adults who require ongoing antiplatelet therapy

• Patients who may benefit from dual antiplatelet therapy in combination with low-dose aspirin

This medication is prescribed under medical supervision as part of a comprehensive cardiovascular care plan.

Dosage and Administration

• The recommended maintenance dose is 60 mg twice daily, taken orally.

• Typically used alongside low-dose aspirin (75–100 mg once daily) for dual antiplatelet therapy.

• Swallow the tablet whole with water; do not crush or chew.

• Take doses at the same times every day to maintain steady platelet inhibition.

• Adherence to the prescribed regimen is essential to reduce the risk of recurrent heart attacks or strokes.

Benefits

• Effectively reduces the risk of recurrent heart attacks and strokes

• Provides rapid and sustained platelet inhibition

• Reversible action allows flexibility in case of bleeding or surgical intervention

• Safe for long-term secondary prevention under medical supervision

• Can be combined with low-dose aspirin for dual antiplatelet therapy

Precautions

• Increased risk of bleeding; avoid in patients with active bleeding, recent hemorrhagic stroke, or bleeding disorders.

• Use with caution in patients with liver impairment or history of intracranial hemorrhage.

• Inform your doctor about any upcoming surgeries, injuries, or use of other anticoagulant medications.

• Monitor for abnormal bleeding signs such as bruising, nosebleeds, or blood in stool/urine.

• Not recommended during pregnancy or breastfeeding unless specifically advised by a physician.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects may include:

• Shortness of breath (dyspnea)

• Headache

• Dizziness or lightheadedness

• Nausea

• Mild bleeding or bruising

Serious side effects requiring immediate medical attention:

• Severe or uncontrolled bleeding

• Severe allergic reactions

• Signs of stroke or heart attack

Storage

• Store below 30°C in a cool, dry place

• Protect from moisture and direct sunlight

• Keep the bottle tightly closed

• Keep out of reach of children

Tiga Tablet 60 mg is a reliable and effective antiplatelet therapy for the secondary prevention of cardiovascular events, providing long-term protection under careful medical supervision.